Portfolio Company · Operating Co.

Suzhou Omini Pharmaeutical

Not on record

backed byVivo Capital

Current

a portfolio company of

Vivo Capital

Status on record: Current

PE Firm Index

Who owns Suzhou Omini Pharmaeutical?

Suzhou Omini Pharmaeutical is listed as a current portfolio company of Vivo Capital on Vivo Capital's own portfolio page.

Company Snapshot

Suzhou Omini Pharmaeutical's owner on record, Vivo Capital, is a firm. Vivo Capital lists at least 98 companies in the index.

SectorNot on record

Parent PE firmVivo Capital

Ownership statusCurrent

WebsiteNot on record

About the owner

Vivo Capital

Companies in the index: At least 98

Health-care focused investment firm.

Read the Vivo Capital profile

Questions about Suzhou Omini Pharmaeutical

Who owns Suzhou Omini Pharmaeutical?

Suzhou Omini Pharmaeutical is listed as a current portfolio company of Vivo Capital on Vivo Capital's own portfolio page.

Sources

Vivo Capital
https://vivocapital.com/portfolio

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Suzhou Omini Pharmaeutical and does not provide investment advice.

Other portfolio companies of Vivo Capital

6 of 97 shown

Aadi Bioscience

Ablaze Pharmaceuticals

Achieve Life Sciences

ADARx Phamaceuticals

Adaxion Therapeutics

Aerobiotix

See the full Vivo Capital portfolio.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Vivo Capital

Status: Current

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.